Frederick National Laboratory Collaboration Success Stories

Accelerator signing ceremony at FITCI on December 10, 2018.Frederick Community Accelerator Program Graduates 11 Businesses

Eleven startup businesses recently graduated from the Edge, a community growth business accelerator founded late last year by Frederick Innovative Technology Center, Inc. (FITCI) in collaboration with Frederick National Laboratory for Cancer Research and many community partners. 


SpaceX's Falcon 9 rocket CRS-16 lifts off from Space Launch Complex 40 on Dec 5, 2018 at Cape Canaveral Air Station, Fla. The CRS-16, a cargo resupply mission to the International Space Station, carried more than 5,600 pounds of supplies to the ISS, including 250 research and science projects. (U.S. Air Force photo by Airman 1st Class Zoe Thacker)Partnerships Blast Off at the Frederick National Laboratory in FY 2018

The national laboratory formed dozens of new collaborations, bringing in millions of dollars in partner contributions to enable vital cancer and HIV/AIDS research. 


An Orbital Sciences Corporation Antares rocket is seen as it launches from Pad-0A at NASA's Wallops Flight Facility, Thursday, January 9, 2014, Wallops Island, VA.Frederick National Laboratory Takes Cancer Research into Space

The Frederick National Laboratory for Cancer Research is taking its science to new heights – with an experiment rocketing into orbit around the Earth. The aim is to grow protein crystals in the weightlessness of space.


This image of a koilocyte shows human ectocervical cells (HEC) expressing HPV-16 E5 oncoprotein, and immortalized with HPV-16 E6 and E7 oncoproteins.New Technical Service Makes HPV Genotyping Available to More Researchers

A new chemical test available through the Frederick National Laboratory for Cancer Research could accelerate human papillomavirus (HPV) research by detecting 40 percent more HPVs than the current gold standard research test. 


Sarah Skoczen, research associate, Nanotechnology Characterization Laboratory, loads samples into the Orbitrap mass spectrometer.Nanotechnology Characterization Laboratory Unveils New Technical Services for Drug Developers

Drug developers now have access to a shared analytical technology, developed and provided by the Frederick National Laboratory, that helps fine-tune nanomedicine formulations and overcomes a key hurdle on the path toward Food and Drug Administration approval of effective new therapies and generic versions of nanomedicines. 


Vaccine being administered IBBR and Frederick National Laboratory Collaborate to Study Vaccine-Boosting Compounds

The Frederick National Laboratory and the University of Maryland’s Institute for Bioscience and Biotechnology Research (IBBR) will work under a formal collaboration to evaluate the effectiveness of new compounds that might be used to enhance the immune response to vaccines.


Human cells with leukemiaNew Partnership Seeks to Increase Availability of Lifesaving Transplants

The Frederick National Laboratory has entered into a new partnership with Fred Hutchinson Cancer Research Center that if successful, could improve current methods of donor selection and thereby make lifesaving transplant procedures more readily available for patients with leukemia, multiple myeloma, and other disorders.


Data Center at the Frederick National LabPublic-Private Consortium Aims to Cut Preclinical Cancer Drug Discovery from Six Years to Just One

The Frederick National Laboratory is part of an unprecedented effort to transform the way cancer drugs are discovered by creating an open and sharable platform that integrates high-performance computing, shared biological data from public and industry sources, and emerging biotechnologies to dramatically accelerate the discovery of effective cancer therapies. 


Surface representation of the structure of oncogenic mutant of KRAS (colored violet) in complex with GTPase-activating proteins (colored light blue).New Partnership Could Help Identify Drugs to Target Cancers Driven by KRAS Mutations

More than 100,000 newly diagnosed cases of cancer each year in the United States are subsequently linked to mutations in the KRAS protein. In response to this urgent problem, a new partnership agreement involving the Frederick National Laboratory could help identify significant therapeutic opportunities to target these types of cancers.